CORBF — Global Cord Blood Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall Cap

Annual income statement for Global Cord Blood, fiscal year end - March 31st, CNY millions except per share, conversion factor applied.

	2018 March 31st	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	20-F	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	937	987	1,221	1,160	1,243
Cost of Revenue
Gross Profit	755	801	1,032	981	1,060
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	657	605	662	615	634
Operating Profit	280	382	559	545	609
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	304	356	579	611	628
Provision for Income Taxes
Net Income After Taxes	241	295	478	516	509
Minority Interest
Net Income Before Extraordinary Items
Net Income	237	291	471	508	501
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	237	291	471	508	501
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.99	2.4	3.87	4.18	4.12